doxorubicin + trastuzumab emtansine

This is a combination therapy consisting of doxorubicin, an anthracycline chemotherapeutic agent, and trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Doxorubicin intercalates into DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and cell death. Trastuzumab emtansine is composed of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1 via a stable thioether linker. Trastuzumab targets HER2-positive cancer cells, delivering DM1 directly to these cells; once internalized, DM1 disrupts microtubule function causing cell-cycle arrest and apoptosis. This combination has been studied in HER2-positive metastatic breast cancer patients who have progressed on prior therapies[1][2]. The rationale for combining these agents is to enhance antitumor efficacy by leveraging both direct cytotoxicity from doxorubicin and targeted delivery from T-DM1.

Other names

ado-trastuzumab emtansineT-DM1T-DM-1T-DM 1DOX